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Abstract 18 
Sulfadoxine/pyrimethamine with amodiaquine is recommended by the World Health Organization as 19 
seasonal malaria chemoprevention for children between 3 to 59 months in the sub-Sahel regions of 20 
Africa. Sub-optimal dosing in children may lead to treatment failure and increased resistance. Pooled 21 
individual patient data from four previously published trials on the pharmacokinetics of sulfadoxine 22 
and pyrimethamine in 415 paediatric and 386 adult patients were analysed using nonlinear mixed 23 
effects modelling to evaluate the current dosing regimen and, if needed, propose an optimised 24 
dosing regimen in children under five years old. The population pharmacokinetics of sulfadoxine and 25 
pyrimethamine were both best described by a one-compartment disposition model, with first-order 26 
absorption and elimination. Body weight, age and nutrition status (measured as weight-for-age z-27 
scores) were found to be significant covariates. Allometric scaling with total body weight and 28 
maturation of clearance in children using post-gestational age improved the model fit. Underweight-29 
for-age children were found to have 15.3% and 26.7% lower bioavailability of sulfadoxine and 30 
pyrimethamine, respectively, for each z-score unit below minus 2. Under current dosing 31 
recommendations, simulation predicted that the median day 7 concentration was below the 25th 32 
percentile of a typical adult patient (50 kg) for sulfadoxine for patients in 8-9, 19-24, 46-49 and 74-79 33 
kg weight bands, and for pyrimethamine for the weight-bands 8-9, 14-24 and 42-49 kg. An evidence-34 
based dosing regimen was constructed that would achieve sulfadoxine and pyrimethamine exposure 35 
in young children and underweight-for-age young children that was similar to that currently seen in 36 
a typical adult.  37 
 38 
  39 
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Introduction 40 
While substantial progress has been made in the recent years to lower mortality rates, malaria 41 
remained the fourth leading cause of death in sub-Saharan children under the age of five in 2015, 42 
with a child dying from malaria every two minutes (1). Children are particularly vulnerable as in 43 
areas of moderate to high intensity transmission, immunity to severe malaria is generally acquired 44 
by the age of five years and immunity to uncomplicated malaria only attained in early adulthood (2).  45 
Malaria treatment outcomes depend on several factors including level of parasite resistance to 46 
antimalarial drugs, host factors such as acquired immunity, and the pharmacokinetic (PK) properties 47 
of the antimalarial treatment. As age and acute malaria may alter the pharmacokinetic properties of 48 
most antimalarial drugs, studies in healthy adult volunteers are not sufficient for determining dosing 49 
regimens in children (3).   50 
Sulfadoxine/pyrimethamine with amodiaquine is recommended by the WHO as seasonal malaria 51 
chemoprevention (SMC) in the Sahel sub-region of Africa in areas with highly seasonal malaria 52 
transmission, where P. falciparum is sensitive to both antimalarial medicines. A full treatment course 53 
of sulfadoxine/pyrimethamine with amodiaquine is administered to children between 3 to 59 54 
months old at monthly intervals during the malaria season (1). 55 
The disposition of sulfadoxine/pyrimethamine in children is poorly understood, even though the 56 
drugs have been used widely for over 50 years. Available data suggests sub-optimal dosing in 57 
children (3). Dosing of antimalarials, such as sulfadoxine/pyrimethamine, has often been based on 58 
age for practical reasons, but this could lead to under- or over-dosing (4). 59 
PK studies are gaining recognition as tools to inform antimalarial drug policies and dosing regimens. 60 
Traditional PK data analysis requires multiple samples per patient, which can be challenging, 61 
particularly in small ill children. Population PK modelling requires less intensive sampling and can 62 
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estimate PK parameters at the population and study arm level, while accounting for individual 63 
differences. This method does well to study the nature of antimalarial drugs in children (5, 6). 64 
There is uncertainty regarding the precise PK determinants of treatment outcome in malaria. There 65 
is evidence that suggests day 7 concentrations (Cday7) are a good determinant of outcome. The 66 
period between dosing and day 7 is crucial because it determines whether the parasite population is 67 
eliminated or causes recrudescence, assuming that drug concentrations will have been above the 68 
day 7 level for 7 days (four 48-hour parasite life-cycles) (7). Toxicity is most likely to be related to the 69 
maximum concentration (Cmax) of the drug, but no threshold for toxicity is reported for 70 
sulfadoxine/pyrimethamine. 71 
In this work, we present a pooled population pharmacokinetic analysis of data from four African 72 
studies (3, 5, 8, 9). The aims of this study were to 1) characterise the pharmacokinetic parameters of 73 
sulfadoxine/pyrimethamine comparing young children to adults using nonlinear mixed-effects 74 
modelling, 2) explore the effect of predefined covariates including nutrition status and 3) if needed, 75 
use simulation to optimise dosing in young children. 76 
 77 
Materials and Methods 78 
All relevant published pharmacology studies were identified by searching PubMed, Embase, Google 79 
Scholar, ClinicalTrials.gov and conference proceedings using the key words ‘sulfadoxine or 80 
pyrimethamine pharmacokinetics’ or ‘sulfadoxine or pyrimethamine concentrations’ and ‘clinical 81 
study’. The first and last authors of identified studies were contacted and invited to join this pooled 82 
analysis by contributing individual patient data to the World Wide Antimalarial Resistance Network 83 
(WWARN) repository as part of a study group if their studies were prospective sulfadoxine and 84 
pyrimethamine studies in African non-pregnant patients with uncomplicated P. falciparum infection, 85 
especially children under the age of five. The WWARN automated data management, curation and 86 
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analysis tools converted the submitted data into a set of defined data variables in a standard format, 87 
following the WWARN clinical and pharmacology data management and statistical analysis plans (10, 88 
11). Study reports were generated from the formatted datasets and sent back to investigators for 89 
validation or clarification. All participating authors agreed to the WWARN terms of submission (12) 90 
that ensure all data uploaded were anonymized and obtained with informed consent, and in 91 
accordance with any laws and ethical approvals applicable in the country of origin. 92 
 93 
The pharmacokinetic data used for modelling was pooled from 4 different previously published 94 
clinical studies (3, 5, 8, 9) from the African countries of Mozambique, South Africa, Mali, and Malawi, 95 
and was collected in 8 different study sites. The data from studies in Mali and Malawi were only 96 
from children while the data from studies in Mozambique and South Africa included both children 97 
and adults. Adults received a single dose of 1500 mg sulfadoxine and 75 mg of pyrimethamine and 98 
children a minimum of 25 mg/kg sulfadoxine and 1.25 mg/kg pyrimethamine according to weight 99 
bands shown in Table 1. Sulfadoxine/pyrimethamine was administered alone (250 children, 304 100 
adults) or in combination with chloroquine (34 children), artesunate (85 children, 113 adults), or 101 
amodiaquine (29 children). All sulfadoxine/pyrimethamine concentrations were measured in 102 
capillary whole blood dried spots on filter paper (n=4214), except in the study conducted by Bell et 103 
al., where concentrations were measured in liquid samples, either capillary (n=285) or venous (n=84) 104 
whole blood. Six to nine samples per patient were collected in all sites at least pre-dose and day 1, 3, 105 
7, 14, 21 and 28. 106 
Nonlinear mixed-effects modelling was implemented in the software Monolix Suite 2016R1 (Lixoft, 107 
France) to analyse the pharmacokinetic data, and parameters were estimated using the Stochastic 108 
Approximation Expectation Maximization (SAEM) algorithm. The pharmacokinetics of sulfadoxine 109 
and pyrimethamine were first modelled independently to determine their structural model and 110 
covariate effects, and then combined into one model to investigate possible correlations between 111 
the pharmacokinetic parameters of the two drugs. One, two, and three compartment disposition 112 
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models with first-order absorption were evaluated for the structural model. Between-subject 113 
variability (BSV) was evaluated on the pharmacokinetic parameters assuming a log-normal 114 
distribution. A combined error model with both additive and proportional components was used for 115 
the residual unexplained variability (RUV). The -2 x log-likelihood value (-2LL), goodness of fit plots, 116 
visual predictive checks (n=1000), residual error plots, and Wald’s test guided the model 117 
development.  118 
All concentration results were available as the original value reported by the analytical laboratory 119 
assay, including the readings below the lower limit of quantification (LLOQ), except for the data 120 
collected in 2 sites in Mozambique, for which all concentrations lower than 10 ng/mL for 121 
pyrimethamine and 10 µg/mL for sulfadoxine were censored and reported as below the LLOQ (BLQ). 122 
These censored values were handled using the M3 approach suggested by Beal (13) using the 123 
censoring functionality in Monolix. All other BLQ readings were used in the model as the original 124 
value reported by the laboratory to make the best use of the data. Drug concentration samples were 125 
collected before dosing to determine if any drug was still present in circulation from previous 126 
treatment. If detectable values were found in these pre-dose samples, it was assumed that the 127 
pharmacokinetic profile was in the terminal elimination phase and all the disposition compartments 128 
in the model were initialised to the observed drug concentration. Biologically implausible samples 129 
were identified and excluded using a model-based approach where values with extreme NPDE’s for 130 
both drugs were discarded. 131 
The effect of weight, age, nutritional status (measured as weight for age z-score; unfortunately, no 132 
data was available on height or mid-upper arm circumference), study site, sex, baseline 133 
haemoglobin, total mg/kg dose, concomitant medications, baseline parasitemia, and sample blood 134 
matrix were tested as predefined covariates.  135 
The effect of body size was taken into account using allometric scaling (14) with total body weight to 136 
adjust all volumes with exponent 1 and flow rates (clearance and flow rates to and from peripheral 137 
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compartments) with exponent 0.75 (15). Unfortunately, no height information was available for the 138 
patients, so testing alternative size descriptors such as fat-free mass or adjustments for BMI were 139 
not possible. The effect of age on clearance (14) was tested using a sigmoidal maturation function of 140 
post-gestational age, as shown below. 141 
𝑀𝐴𝑇 =
𝑃𝐺𝐴𝛾
𝑃𝐺𝐴𝛾 + 𝑃𝐺𝐴50
𝛾 
(1) 
where PGA is the post gestational age, PGA50 is PGA at which the clearance is 50% that of the mature 142 
value, and γ is the Hill coefficient determining the steepness of the curve.  143 
The nutritional status of children was determined based on weight for age z-scores calculated using 144 
the R macro and igrowup.standard function provided on the WHO website (16). The weight-for-age 145 
z-score is determined from growth curves developed by the WHO Multicentre Growth Reference 146 
Study (MGRS). It was undertaken between 1997 and 2003 to generate new growth curves for 147 
assessing the growth and development of infants and young children around the world. The MGRS 148 
collected primary growth data and related information from approximately 8500 children from 149 
widely different ethnic backgrounds and cultural settings (Brazil, Ghana, India, Norway, Oman and 150 
the USA). Children were considered malnourished if they had a z-score less than -2 (17). This effect 151 
was added to the model using a “hockey stick” model, according to the formula equation 2.  152 
𝐸𝑓𝑓𝑒𝑐𝑡 = (𝑐ℎ𝑎𝑛𝑔𝑒 𝑖𝑛 𝑏𝑖𝑜𝑎𝑣𝑎𝑖𝑙𝑎𝑏𝑖𝑙𝑖𝑡𝑦 𝑝𝑒𝑟 𝑢𝑛𝑖𝑡 𝑐ℎ𝑎𝑛𝑔𝑒 𝑖𝑛 𝑧 − 𝑠𝑐𝑜𝑟𝑒)  × (𝑧 − 𝑠𝑐𝑜𝑟𝑒 + 2) (2) 
  
For other categorical covariates (study site, sex, concomitant medications, and sample blood matrix), 153 
one reference sub-category (REF) was defined and relative differences from REF were calculated for 154 
each of the other sub-categories. For other continuous covariates (baseline haemoglobin, mg/kg 155 
dose and, baseline parasitemia), the linear covariate effects on the log-transformed PK parameters 156 
were explored, centred on the median value in the population in order to incorporate the central 157 
tendency of the data as shown in equation 3.   158 
𝐿𝑜𝑔(𝑃𝑖)  =  𝑙𝑜𝑔(𝑃𝑝𝑜𝑝)  +  𝛽 𝑙𝑜𝑔 (𝑐𝑜𝑣/𝑚)  +  𝜂𝑖 
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where Pi is the individual parameter value, Ppop is the population parameter value, β is the covariate 159 
effect, cov is the continuous covariate, m is the median value and ηi is the random effect for 160 
parameter Pi. This ensures that positive PK parameters are preserved and the effect can be 161 
interpreted approximately as a relative change in parameter value for a unit change in the covariate. 162 
In case of several categorical and/or continuous covariate effects on the same PK parameter, all 163 
effects were included using a multiplicative relationship. 164 
Covariate effects were screened for using the “full approach”, where all effects with potential impact 165 
on sulfadoxine/pyrimethamine PK are estimated simultaneously, and tested for statistical 166 
significance using the Wald test (p-value<0.05). The covariate effects detected as significant with the 167 
Wald Test were then included in the model with a step-wise approach. First, they were added one by 168 
one and retained if they produced a decrease in the -2LL of more than 3.84 for one degree of 169 
freedom (p<0.05). Then, they were confirmed with a backward elimination step, where each 170 
covariate-PK parameter relationship was removed one by one, and retained only if an increase 171 
greater than 10.83 in -2LL for one degree of freedom (p<0.001) was observed. 172 
No widely-accepted PK targets for either efficacy or toxicity are available for 173 
sulfadoxine/pyrimethamine, and effective concentrations increase with the accumulation of 174 
dihydrofolate reductase and dihydropteroate synthase mutations. The clinical dataset contained 175 
data on a large number of patients where adults achieved high efficacy and in both adults and 176 
children very little toxicity was reported. It was therefore decided pragmatically to target the 177 
concentrations that the model predicted for the patients included in our analysis. Median values of 178 
Cday7 and Cmax were chosen as reference values with the same tolerance threshold. The use of the 179 
25% tolerance margin was dictated by pragmatic considerations, to accommodate for the feasibility 180 
of the suggested optimised regimen in a programmatic setting (i.e., to avoid the creation of too 181 
many weight-bands and/or the breaking of tablets). 182 
 o
n
 M
arch 7, 2018 by LIVERPO
O
L SCH O
F TRO
PICAL M
ED
http://aac.asm
.org/
D
ow
nloaded from
 
9 
 
Monte Carlo simulations based on the final PK model were used to evaluate dosing regimens. The 183 
median Cday7 for a typical 50 kg patient, after standard recommended dosing, were simulated and 184 
efficacy targets were fixed to 75% of these values. The median Cmax were simulated and toxicity 185 
thresholds were fixed to 125% of the highest value amongst the weight -bands with good 186 
representation in our clinical data. Dosing regimens were evaluated based on whether they achieved 187 
median Cday7 higher than the efficacy targets and median Cmax lower than the toxicity thresholds for 188 
patients with different bodyweights. We first evaluated the currently recommended WHO dosing 189 
regimen (18) and then explored alternative dosing regimens. Historical malaria patient data from 190 
several studies (19–26), and unpublished data from routine clinical monitoring of malaria infected 191 
children (under five years) patients and the patients used in this study, were used to create a model 192 
describing weight for age in malaria patients (appendix 1). This model was used to simulate plausible 193 
weight for age values: 20 in silico patients were generated for each kilogram of weight between 5 to 194 
80 kg. In weight bands that contained children under the age of five, in which age-for-weight z-195 
scores are defined, 40 more patients per kg (20 with z-score < -3 and 20 with -3 ≤ z-score < -2) were 196 
simulated (60 patients in total per each bodyweight in kg). None of the simulated patients had z-197 
scores less than -4.27, as no patients in the studies pooled for our PK analysis had a z-score less than 198 
-4.27. The resulting database had 1880 in silico malaria patients with age between 1 and 50 years. 199 
The current WHO dosing guidelines were simulated in 500 hypothetical clinical trials using the 1880 200 
in silico patients and the final developed population PK model. 201 
Results 202 
Data 203 
Pharmacokinetic data was collected in 801 patients, 415 of whom were children (Table 1). 259 out of 204 
8981 (2.88%) samples were excluded as outliers (i.e. biologically implausible), resulting in a total of 205 
4567 blood concentrations for sulfadoxine and 4155 for pyrimethamine available for analysis. There 206 
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were 152 (18.9%) and 125 (15.6%) patients with detectable but low pre-dose concentrations of 207 
sulfadoxine and pyrimethamine, respectively. 208 
Pharmacokinetic Model 209 
A 1-compartment model with first-order absorption and elimination provided the best fit for both 210 
sulfadoxine and pyrimethamine. The combined model for both sulfadoxine and pyrimethamine 211 
supported between-subject variability in clearance, volume of distribution, absorption rate constant, 212 
and bioavailability and a combined error structure. The final model parameter values are shown in 213 
Table 2. Prediction-corrected visual predictive checks, to adjust for the site effects, of the observed 214 
drug concentrations versus time are shown in Figure 1. Additionally, visual predictive checks 215 
(without prediction correction) stratified by study site and age and other goodness of fit plots 216 
stratified by age, weight and nutrition score are included in the supplementary material. These plots 217 
show that the median of the observed data generally fits well within the confidence interval for the 218 
50th percentile of the model prediction in each age category, although some sites and age groups 219 
displayed more variability than others and the model would sometimes over- or under-predicted the 220 
extreme percentiles. The model simulations used for dose optimisation were therefore performed 221 
with the parameter values of the reference site - which contained most patients (55% for 222 
sulfadoxine and 53% for pyrimethamine) – and targeting median values, which were more 223 
consistently well predicted. 224 
Allometric scaling with total body weight improved the model fit substantially (S: Δ-2LL=320 P: Δ-225 
2LL=855) and decreased BSV in volume of distribution for both drugs. Maturation of clearance 226 
improved the model fit and decreased the -2LL by 47 points (S: Δ-2LL=15, df=2 p<0.001; P: Δ-2LL=32, 227 
df=2 p<0.001). Malnutrition, as characterised by low weight for age z-score, was found to affect 228 
bioavailability (S: Δ-2LL=21, df=2, p<0.001; P: Δ-2LL=81, df=2, p<0.001), with children who had a z-229 
score of -3 having 15.3% and 26.7% lower bioavailability of sulfadoxine and pyrimethamine, 230 
respectively than children with a z-score greater or equal to -2. 231 
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Even after adjusting for body size, maturation, and nutrition score, significant site-specific 232 
differences between the pharmacokinetic profiles remained. For sulfadoxine, compared to the 233 
reference group (Magude, Bancoumana, Bela Vista, Catuane, Chileka), group A (Mpumalanga, 234 
Boane, Namaacha) had 39.7% lower observed concentrations (Δ-2LL=263, df=1, p<0.001). For 235 
pyrimethamine, compared to the reference group (Magude, Mpumalanga, Boane, Chileka), group B 236 
(Catuane, Bancoumana, Bela Vista) had 22% higher observed concentrations (Δ-2LL=1342, df=1, 237 
p<0.001) and group C (Namaacha) 20.2% lower observed concentrations (Δ-2LL=183, df=1, p<0.001). 238 
The Bell et al. study had a 54.9% lower pyrimethamine clearance (Δ-2LL=3668, df=1, p<0.001) 239 
compared to the other sites. No other pre-defined covariates (sex, baseline haemoglobin, mg/kg 240 
dose, concomitant medications and baseline parasitemia) were found to be significant and these 241 
were therefore excluded from the model. 242 
The simulated (n=500) median day 7 concentrations (Cday7) for a typical 50 kg patient were 81.7 243 
µg/mL for sulfadoxine and 132 ng/mL for pyrimethamine after standard WHO recommended dosing. 244 
Efficacy targets were fixed to 75% of these values: 61.3 µg/mL for sulfadoxine and 98.9 ng/mL for 245 
pyrimethamine. The simulations also revealed that, median maximum concentrations (Cmax) for a 246 
typical 10 kg patient (highest Cmax amongst the weight-bands with good representation in our 247 
clinical data) were 263 µg/mL for sulfadoxine and 785 ng/mL for pyrimethamine and toxicity 248 
thresholds 329 µg/mL and 981 ng/mL respectively (125% of median value).  249 
Under the current dosing recommendations, patients who weigh 8-9, 19-24, 46-49 and 74-79 kg 250 
showed simulated median sulfadoxine Cday7 lower than the efficacy target for sulfadoxine, while for 251 
pyrimethamine this occurred in the weight-bands 8-9, 14-24 and 42-49 kg. Optimised weight-based 252 
dosing using a maximum of five weight bands given 0.5, 1, 1.5, 2, 3 and 4 tablets of 500 mg 253 
sulfadoxine/25 mg pyrimethamine were simulated. The optimised dose that achieved median Cday7 254 
higher than the efficacy target and median Cmax lower than the toxicity threshold is shown alongside 255 
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the current WHO dosing regimen in Table 3, and in Figure 2 and Figure 3 for sulfadoxine and 256 
pyrimethamine, respectively.  257 
Under current dosing recommendations, among children with a body weight of 10 kg, moderate 258 
malnutrition (z-score between -2 and -3) resulted in 6.68% and 21.9% lower median Cday7 for 259 
sulfadoxine and pyrimethamine, respectively, while severe malnutrition (z-score less than -3) 260 
resulted in 20.3 % and 44.3% lower median Cday7 for sulfadoxine and pyrimethamine, respectively 261 
(Figure S2, in supplementary material). Thus, an alternative age-based dosing regimen for children 262 
under the age of five was explored. A comparison of the weight-based and age-based optimised 263 
dosing regimens, to achieve a median Cday7 higher than the efficacy target and median Cmax lower 264 
than the toxicity threshold for each weight or age band, is shown in Table 4, with simulated Cday7 and 265 
Cmax for the optimised weight-based and age-based dosing regimens presented in Figure 4 and Figure 266 
5, respectively. 267 
 268 
Discussion 269 
In this study, a population pharmacokinetic nonlinear mixed-effects model was used to analyse data 270 
pooled from four studies in eight study sites. The overall aim was to describe the pharmacokinetic 271 
properties of sulfadoxine and pyrimethamine in paediatric and adult malaria patients, characterise 272 
the effect of clinical and demographic covariates, and design an optimised dosing regimen. The most 273 
significant differences between adults and children were found to be body size (accounted for with 274 
allometric scaling) and age, affecting maturation of organ function. Additionally, children who were 275 
underweight-for-age had lower bioavailability compared to adequately nourished children. 276 
Simulation-based predictions revealed that patients with a body weight of 8-9, 19-24, 46-49 and 74-277 
79 kg for sulfadoxine and 8-9, 14-24 and 42-49 kg for pyrimethamine, did not reach the chosen 278 
efficacy target with the current dosing recommendation. Based on the model, a revised dosing 279 
regimen was devised and is expected to provide therapeutic exposures in small children similar to 280 
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adults, which could improve malaria treatment in children under the age of five and provide insight 281 
into dosing for chemoprevention in children. 282 
To our knowledge, this study is the largest analysis of the pharmacokinetics of 283 
sulfadoxine/pyrimethamine to date (3, 5, 8, 9, 27–29), pooling data from four different clinical 284 
studies, for a total of 8722 pharmacokinetic samples in 801 patients in Africa, of whom 415 were 285 
children. Pooling of these data empowers it to address novel research questions and detect new 286 
covariate effects (30) for which the single studies were not adequately powered, such as the effect 287 
of malnutrition. Our results can be used to inform treatment regimens in children, one of the most 288 
vulnerable groups affected by malaria (1). 289 
The final model has estimated parameters with comparable values to those in previous studies 290 
(Table 5) with high precision and acceptable model diagnostics. Allometric scaling significantly 291 
explained some of the differences between adults and children by accounting for changes in body 292 
size. No information on patient height was available, so we could not attempt to adjust for body 293 
composition and test fat-free mass for scaling, which could arguably be a better predictor for the 294 
size of drug-metabolising organs (31). The absence of height information in children was more of a 295 
limitation when trying to determine the nutritional status of the children. We could only calculate 296 
weight-for-age z-scores as a measure of nutritional status and no attempt could be made to 297 
distinguish between stunting and wasting. Children who were underweight for age were found to 298 
have lower bioavailability than adequately nourished children in the study. This could be due to 299 
decreased or delayed absorption of the drugs, or possibly to increased total body water, lower 300 
albumin levels, or other pathophysiological changes observed in malnourished children (32). As both 301 
sulfadoxine and pyrimethamine are highly protein bound (90%), lower levels of albumin may cause 302 
higher free drug concentrations resulting in higher clearance and larger volume of distribution, 303 
which would have the same effect on the PK profile as a decrease in bioavailability. However, 304 
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changes in protein binding are not expected to affect unbound drug levels, so no dose adjustment 305 
would be necessary.  306 
The inclusion of allometric scaling could not fully explain the pharmacokinetics in children younger 307 
than 2 years old, due to the significant maturation of drug clearing organs (14, 33). This was 308 
described in the model with the inclusion of a maturation function accounting for the fact that 309 
young children have a lower clearance than adults, after adjusting for the effect of body size. The 310 
model estimated the age (months after conception) at which maturation reaches half of its maximal 311 
value (PGA50) at around 8.1 months for sulfadoxine and 11.9 months for pyrimethamine, similarly to 312 
previous values reported by Salman et al. (34), 9.03 months for sulfadoxine and 10.6 months for 313 
pyrimethamine. As renal function and many hepatic enzymes are expected to reach maturity by age 314 
2 (35), a limitation is that our study does not contain data on children under the age of 1. More 315 
information is therefore needed to assess fully the effect of maturation on clearance in infants. 316 
Even after adjusting for body size, maturation, and nutrition score, significant site-specific 317 
pharmacokinetic differences remained. We could include 55% of patients for sulfadoxine and 53% of 318 
patients for pyrimethamine in the reference site, but for patients in other sites an adjustment factor 319 
was needed. Additionally, the study by Bell et al. was found to have a 54.9% slower clearance than in 320 
the other sites. This study was the only one that assayed whole blood liquid samples (capillary dried 321 
blood spot samples were assayed in all the other studies) and its samples were assayed in a different 322 
lab. Thus, it was not possible to determine whether this difference is explained by matrix, assay 323 
method and / or population-specific factors. 324 
Young children in areas of high malaria transmission are particularly vulnerable, as immunity is 325 
acquired with age and after repeated infections (2). Malaria-induced inflammation can also cause 326 
iron deficiency anaemia in children with asymptomatic malaria (36). It is therefore important that 327 
children receive adequate doses of sulfadoxine/pyrimethamine as treatment. Appropriate drug 328 
dosing in children is particularly challenging (3) and a number of studies have reported sub optimal 329 
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exposures for children receiving antimalarial treatment (3, 8, 9). The final model developed in this 330 
study demonstrated sufficient predictive performance, deeming it suitable for dose optimisation 331 
simulations. It was therefore used to simulate sulfadoxine/pyrimethamine exposures for different 332 
body weights with the current dosing guidelines and to develop optimised weight-based and age-333 
based dosing regimens. A proposed optimised dosing regimen based on simulations is provided for 334 
the range of weights of 5-79 kg. The weight bands were designed using the currently available tablet 335 
size, and allowing only multiple of half tablets. No widely-accepted PK targets for either efficacy or 336 
toxicity are available for sulfadoxine or pyrimethamine, therefore  efficacy was prioritised, since 337 
adverse reactions are infrequent and severe cutaneous toxicity is rare and idiosyncratic (and not 338 
dose-related) (37). Furthermore, pyrimethamine has also been used safely in children at doses as 339 
high as 2 mg/kg for the treatment of toxoplasmosis (38). However, more precise definitions of 340 
efficacy and safety thresholds would further improve, and potentially simplify, dosage 341 
recommendations.  342 
Alternate optimised dosing in age bands rather than weight bands (Table 4) for children under five 343 
years, was proposed to address the concerning finding of significantly lower sulfadoxine and 344 
pyrimethamine exposure in underweight-for-age young children, and resulted in more satisfactory 345 
exposures. Age-based dosing shows a lot of promise for malnourished children, but further data 346 
would be needed for drawing definitive conclusions on optimal dosing in this doubly vulnerable 347 
population. 348 
Although very young patients (1 – 12 months) were included in the weight-for-age data set, we did 349 
not have any patient data below the age of 12 months in the pharmacokinetic dataset used to build 350 
the model. Simulated optimised dosing for children less than 12 months (125 mg / 6.25 mg 351 
sulfadoxine / pyrimethamine for less than 5 kg) was made possible by inclusion of a maturation 352 
function in the model. However, further pharmacokinetic data is needed for investigation into the 353 
maturation of clearance of sulfadoxine and pyrimethamine in children under 12 months to inform 354 
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optimal dosing in this age group. This is reflected by the relative standard error (56% for Sulfadoxine 355 
and 13% for Sulfadoxine) in the parameter for post gestational age at which CL is 50% that of the 356 
mature value (PGA50).  357 
 358 
Conclusions 359 
This study reports the largest pharmacokinetic analysis of sulfadoxine/pyrimethamine to date and 360 
proposes a model accounting for the effect of body size, maturation, and nutritional status. The 361 
analysis revealed suboptimal sulfadoxine/pyrimethamine exposures in some weight bands when 362 
given the current WHO recommended dose regimens. Children who were underweight-for-age had 363 
decreased bioavailability, with a greater effect on pyrimethamine. Accounting for all these effects, 364 
the model was used to propose an optimised sulfadoxine/pyrimethamine dosing regimen, essential 365 
to ensure that children, and particularly malnourished children, achieve similar exposures to adults 366 
and so have an equivalent likelihood of treatment success. Improved treatment success would 367 
reduce the selective pressure for the development of resistance and prolong the useful therapeutic 368 
life-span of sulfadoxine/pyrimethamine.  369 
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Table 1: Population characteristics of pharmacokinetic studies included stratified by study and site.  
Parameter 
Study Total 
Barnes 
et al. (4) 
Bell et al. (9) 
Tekete 
et al. (12) 
Allen 
et al. (13) 
 Site 
Bela Vista Mpumalanga Namaacha Chileka Bancoumana Boane Cutuane Magude Namaacha 
N 65 122 91 102 114 78 33 124 72 801 
Sampling times 
Blood samples 
collected  
Before dosing 
and day 1, 2, 3, 
7, 14, 21, 28, 42 
post dosing. 
Before dosing 
and day 1, 2, 
3, 7, 14, 21, 
28, 42 post 
dosing. 
Before dosing 
and day 1, 2, 
3, 7, 14, 21, 
28, 42 post 
dosing. 
Before dosing 
and day 2, 3, 
7, 14, 28 post 
dosing. 
Before dosing 
and day 1, 3, 
7, 14, 21, 28 
post dosing. 
Before 
dosing and 
day 1, 2, 3, 
7, 14, 21, 28, 
42 post 
dosing. 
Before 
dosing and 
day 1, 2, 3, 
7, 14, 21, 28, 
42 post 
dosing. 
Before 
dosing and 
day 1, 2, 3, 
7, 14, 21, 28, 
42 post 
dosing. 
Before 
dosing and 
day 1, 2, 3, 
7, 14, 21, 28, 
42 post 
dosing. 
 
Dose: Number of tablets (500mg/25mg SP) 
< 10 kg 
1 1 1 
1/2 1/2 N/A N/A N/A N/A 
 
10 – 14 kg 3/4 
3/4 
1 1 1 1 15 kg 
1 
16 - 20 kg 1 
21 – 22 kg 
2 2 2 
1 1/4 1 1/4 
2 2 2 2 
23 – 35 kg 
N/A N/A 36 - 40 kg 
3 3 3 3 
>40 3 3 3 
Sex 
Male 30 (46%) 72 (59%) 48 (53%) 57 (56%) 63 (55%) 31 (40%) 18 (54%) 45 (36%) 34 (47%) 398 (50%) 
Age 
< 2 0 (0%) 0 (0%) 19 (20%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 13 (18%) 32 (4%) 
>2 – 5 38 (58%) 2 (1.6%) 25 (22%) 102 (100%) 114 (100%) 14 (18%) 11 (33%) 48 (39%) 29 (35%) 383(47%) 
>5 – 20 17 (26%) 66 (54%) 20 (19%) 0 (0%) 0 (0%) 23 (29%) 17 (52%) 44 (35%) 10 (13%) 197 (25%) 
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20+ 10 (15%) 54 (44%) 27 (30%) 0 (0%) 0 (0%) 41 (52%) 5 (15%) 32 (26%) 20 (28%) 189 (24%) 
Treatment arm 
SP 65 (100%) 122 (100%) 91 (100%) 28 (27%) 41 (36%) 28 (36%) 17 (52%) 63 (51%) 35 (49%) 490 (61%) 
SP + AQ 0 (0%) 0 (0%) 0 (0%) 20 (20%) 40 (35%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 60 (7%) 
SP + CQ 0 (0%) 0 (0%) 0 (0%) 26 (25%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 26 (3%) 
SP + AR 0 (0%) 0 (0%) 0 (0%) 28 (27%) 33 (29%) 50 (64%) 16 (48%) 61 (49%) 37 (51%) 225 (28%) 
Nutrition score in children under 5 years 
Normal 36 (95%) 2 (100%) 43 (98%) 86 (85%) 102 (89%) 7 (50%) 11 (100%) 29 (60%) 29 (100%) 326 (85%) 
-3 <= z-score < -2 2 (5%) 0 (0%) 0 (0%) 15 (14%) 7 (6%) 4 (28%) 0 (0%) 13 (27%) 0 (0%) 41 (11%) 
z-score < -3 0 (0%) 0 (0%) 1 (2%) 1 (1%) 5 (5%) 3 (22%) 0 (0%) 6 (13%) 0 (0%) 16 (4%) 
Weight 
Median weight 
[IQR] in kg 
15 [12 - 37] 50 [32 - 58] 26 [13 - 55] 11 [9 - 12] 14 [11 - 16] 55 [32 - 63] 32 [15 - 45] 25 [14 - 50] 15 [12 - 54] 18 [12 - 50] 
Baseline Haemoglobin 
Median baseline 
haemoglobin 
[IQR] in g/dL 
11 [10 - 12] 12 [11 - 13] 11 [10 - 12] 9 [8 - 10] 11 [9 - 12] 11 [10 - 14] 12 [11 - 13] 11 [10 - 12] 11 [9 - 13] 11 [10 - 12] 
Baseline Parasitaemia 
Geometric mean 
baseline 
parasitaemia 
[95% range] in 
count/µL 
16028 [2140 - 
96995] 
22522 [1870 - 
169992] 
19874 [2065 - 
211999] 
52717 [2364 - 
212647] 
41694 [7282 - 
138275] 
5719 [62 - 
99646] 
768 [41 - 
64200] 
1853 [15 - 
143277] 
12561 [82 - 
290493] 
21700 
[4532 - 
63083] 
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Table 2: Parameter estimates for final combined sulfadoxine/pyrimethamine population 
pharmacokinetic model. 
Parameter 
Sulfadoxine Pyrimethamine 
Estimate RSE (%)ᵃ Estimate RSE (%)ᵃ 
F 1 fixed - 1 fixed - 
CL/F [L/h] ᵇ 0.0264 3 0.829 3 
V/F [L] ᵇ 5.29 2 91.4 3 
ka [/h] 0.521 16 1.40 80 
Change in F for each point in z-score below -2 [%] -15.3 31 -26.7 13 
PGA50 [months after conception]  8.12 56 11.9 13 
γ -Hill coefficient 3.20 21 3.01 46 
Difference in clearance in Bell et al. [%] - - -54.9 4 
Scaling on observations in Bancoumana, Bela Vista, 
Catuane [%] 
#
 
- - 20.2 19 
Scaling on observations in Namaacha [%] 
#
 - - -22.0 23 
Scaling on observations in Mpumalanga, Boane, 
Namaacha [%] * 
-39.7 5 - - 
BSV in F [%] 
c
 38.4 12 36.1 4 
BSV in ka [%]
 c
 126 21 171 25 
BSV in V [%]
 c
 11.2 23 15.5 14 
BSV in Cl [%]
 c
 33.9 5 29.0 5 
Correlation in CL of the two drugs [%] 60.0 6 60.0 6 
Additive error [ug/mL for sulfadoxine; ng/mL for 
pyrimethamine] 
3.79 5 6.58 5 
Proportional error [%] 17.1 3 23.2 2 
RSE, relative standard error; F, relative bioavailability; CL/F, elimination clearance for a fully matured child; V/F, apparent 
volume of distribution; ka, first-order absorption rate constant; PGA50 is the PGA at which CL is 50% that of the mature 
value; BSV, between subject variability. 
ᵃ RSE (%) is calculated from the Fisher information determined by stochastic approximation. 
ᵇ Clearance and volume were allometrically scaled with total body weight centred on the median body weight (18 kg). 
c 
BSV were assumed as log-normally distributed and are reported here as approximate CV% 
* Reference group for scaling on observation for sulfadoxine: Magude, Bancoumana, Bela Vista, Catuane, Chileka. 
#  
Reference group for scaling on observation for pyrimethamine: Magude, Mpumalanga, Boane, Chileka. 
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Table 3: Dose-optimisation simulations. 
 
 
Current WHO dosing 
recommendations (ref 17) 
Optimised dosing 
recommendations (for 
patients older than 1 year) 
Number of tablets  
(500 mg/25 mg SP) 
Dose Weight Weight 
0.5 250mg / 12.5mg SP 5 – 9 kg < 8kg 
1 500mg / 25mg SP 10 – 24 kg 8 – 13 kg 
1.5 750mg / 37.5mg SP - 14 – 24 kg 
2 1000mg / 50mg SP 25 – 49 kg 25 – 38 kg 
2.5 1250mg / 62.5mg SP - 39 – 49 kg 
3 1500mg / 75mg SP ≥ 50 kg 50 – 68 kg 
4 2000mg / 100mg SP - ≥ 69 kg 
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Table 4: Optimised dosing proposal for patients under 60 months of age: Weight-based (left) and 
age-based dosing (right). 
Weight-based optimised dosing Age-based optimised dosing 
Weight 
(kg) 
Number of tablets 
(500 mg/25 mg SP) 
Dose Age 
(months) 
Number of tablets 
(500 mg/25 mg SP) 
Dose 
< 8 0.5 250 mg / 12.5 mg SP < 16 0.5 250 mg / 12.5 mg SP 
8 – 13 1 500 mg / 25 mg SP 16 – 41 1 500 mg / 25 mg SP 
14 – 25 1.5 750 mg / 37.5 mg SP 42 – 60 1.5 750 mg / 37.5 mg SP 
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Table 5: Other published studies of sulfadoxine/pyrimethamine pharmacokinetic data in patients with uncomplicated malaria 
Author ,year  
(reference) 
Sarikabhuti et al, 1988 (31)  Hellgren et al, 
1990 (32) 
Winstanley et al, 
1992 (33) 
Bustos et al, 2002 
(34) 
Dzinjalamala et al, 
2005 (28) 
Obua et al, 2008 (35)a 
Assay Bratton-Marshall HPLC HPLC HPLC HPLC HPLC 
Patient group Adults with malaria Children (8-14 
years) with 
malaria 
Children with 
malaria  
Adults with malaria Children (1-12 years) 
with malaria 
Children (2-5 Years) with 
malaria 
Number of 
participants 
Responders, 5 
Non-responders, 7 
10 8 Sulfadoxine,19 
Pyrimethamine,13 
ACPR, 49 
LTF, 66 
55 
Sample Type Plasma Capillary whole 
blood 
Plasma Serum Capillary whole blood 
spots on filter paper 
Capillary whole blood 
spots on filter paper 
Statistic Median  
(range) 
Median (range) Mean Median  
(range) 
Mean Mean  
(range) 
Sulfadoxine 
Dose 500 mg  29.4 (25.0 - 35.7) 
mg/kg 
25 mg/kg 1500 mg ACPR: 34.7 mg/kg  
LTF: 32.3 mg/kg 
500 mg 
Cmax (µg/mL) Responders: 160 (151 - 176) 
Non-responders: 192 (143 - 
243) 
94 (78 - 103) 79 169 (124 - 279) ACPR: 79 
LTF: 69 
171 (85 - 249) 
AUC (µg/mL/h) Responders: 45,792 
(34,656 - 61,560) 
Non-responders: 43,392 
(32,256 - 55,344) 
23,064  
(13,176 - 28,992) 
20,016 66,192  
(42,480 - 93,552) 
ACPR: 22,368 
LTF: 21,312 
16,900  
(2,840 - 27,500) 
T1/2 (h) Responders: 228  
(165.6 - 273.6) 
Non-responders: 184 (172.8 
- 252) 
214 (125 - 242) 115.2 261.6 (158.4 - 
321.6) 
ACPR: 172 
LTF: 154 
98 (18 -177) 
Pyrimethamine 
Dose   1.25 mg/kg 75 mg   
Cmax (ng/mL)   533 591 (173 - 815)   
AUC (ng/mL/h)   62,568 72,696  
(28,584 - 161,904) 
  
T1/2 (h)   81.6 69.6 (38.4 - 302.4)   
ACPR, adequate clinical and parasitological response; LTF, late treatment failures; Cmax, maximum concentration; AUC, Area under the curve; T1/2, elimination half-life; a AUC from 0 to 336h  
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